Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Enhanced intracellular delivery and antibacterial efficacy of enrofloxacin-loaded docosanoic acid solid lipid nanoparticles against intracellular Salmonella.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
- Publication Information:
Original Publication: London : Nature Publishing Group, copyright 2011-
- Subject Terms:
- Abstract:
Enrofloxacin-loaded docosanoic acid solid lipid nanoparticles (SLNs) with different physicochemical properties were developed to enhance activity against intracellular Salmonella. Their cellular uptake, intracellular elimination and antibacterial activity were studied in RAW 264.7 cells. During the experimental period, SLN-encapsulated enrofloxacin accumulated in the cells approximately 27.06-37.71 times more efficiently than free drugs at the same extracellular concentration. After incubation for 0.5 h, the intracellular enrofloxacin was enhanced from 0.336 to 1.147 μg/mg of protein as the sizes of nanoparticles were increased from 150 to 605 nm, and from 0.960 to 1.147 μg/mg of protein when the charge was improved from -8.1 to -24.9 mv. The cellular uptake was more significantly influenced by the size than it was by the charge, and was not affected by whether the charge was positive or negative. The elimination of optimal SLN-encapsulated enrofloxacin from the cells was significantly slower than that of free enrofloxacin after removing extracellular drug. The inhibition effect against intracellular Salmonella CVCC541 of 0.24 and 0.06 μg/mL encapsulated enrofloxacin was stronger than 0.6 μg/mL free drug after all of the incubation periods and at 48 h, respectively. Docosanoic acid SLNs are thus considered as a promising carrier for intracellular bacterial treatment.
- References:
Cell Mol Life Sci. 2009 Sep;66(17):2873-96. (PMID: 19499185)
Biomaterials. 1988 Jul;9(4):356-62. (PMID: 3214660)
Dtsch Tierarztl Wochenschr. 2005 Jun;112(6):219-23. (PMID: 16028487)
J Control Release. 2014 Aug 10;187:101-17. (PMID: 24878179)
Int J Pharm. 2007 Dec 10;345(1-2):154-62. (PMID: 17624699)
Biochim Biophys Acta. 1984 Apr 25;772(1):93-101. (PMID: 6712952)
Antimicrob Agents Chemother. 1995 Sep;39(9):2104-11. (PMID: 8540724)
Colloids Surf B Biointerfaces. 2011 Apr 1;83(2):382-7. (PMID: 21215599)
J Biol Chem. 1995 Jul 7;270(27):16221-4. (PMID: 7541795)
Emerg Infect Dis. 2014 Jan;20(1):167-9. (PMID: 24377875)
J Control Release. 2008 Feb 11;125(3):210-27. (PMID: 18077047)
Clin Infect Dis. 2012 Jun;54 Suppl 5:S472-9. (PMID: 22572672)
Nat Rev Microbiol. 2008 Jan;6(1):53-66. (PMID: 18026123)
Microbes Infect. 2010 Oct;12(11):809-18. (PMID: 20538070)
J Antimicrob Chemother. 2004 Feb;53(2):396-8. (PMID: 14711838)
Antimicrob Agents Chemother. 1999 Sep;43(9):2138-43. (PMID: 10471554)
Vet Ther. 2001 Fall;2(4):334-44. (PMID: 19746656)
J Biomed Mater Res. 2002 Aug;61(2):246-51. (PMID: 12007205)
J Pharm Pharmacol. 2007 Jan;59(1):75-80. (PMID: 17227623)
J Vet Med B Infect Dis Vet Public Health. 2002 Aug;49(6):289-93. (PMID: 12241030)
J Drug Target. 2006 Sep;14(8):557-66. (PMID: 17043040)
Drug Dev Ind Pharm. 2008 Oct;34(10):1090-6. (PMID: 18777242)
- Accession Number:
0 (Anti-Bacterial Agents)
0 (Fatty Acids)
0 (Fluoroquinolones)
0 (Lipids)
3DX3XEK1BN (Enrofloxacin)
H390488X0A (behenic acid)
- Publication Date:
Date Created: 20170124 Date Completed: 20181018 Latest Revision: 20240523
- Publication Date:
20240523
- Accession Number:
PMC5253767
- Accession Number:
10.1038/srep41104
- Accession Number:
28112240
No Comments.